short bowel syndrome
Gastroenterology · 2015–2019
Every decision
| Medicine | Meeting | Outcome | Consumer input |
|---|---|---|---|
| teduglutide Treatment of patients with Type III (chronic) intestinal failure associated with short bowel syndrome who are dependent on parenteral support. | Mar 2019 | Recommended | 1 individuals |
| teduglutide Type III (chronic) intestinal failure associated with short bowel syndrome in patients dependent on parenteral support for at least 12 months with stable… | Jul 2018 | Not recommended | input received |
| teduglutide Treatment of patients with Type III (chronic) intestinal failure associated with short bowel syndrome who are stable on parenteral support. | Nov 2017 | Not recommended | input received |
| amino acid synthetic formula supplemented with long chain polyunsaturated fatty acids and medium chain triglycerides Eosinophilic oesophagitis and severe intestinal malabsorption including short bowel syndrome (Alfamino®); eosinophilic oesophagitis (Alfamino® Junior). | Nov 2015 | Recommended with restriction | none received |
What the PBS pays
$22M in government benefit over 2024–25, across 37,974 services.
This is spend on the medicines considered for this condition, not spend on the disease. A medicine used for several conditions is counted in full under each, so figures across conditions add to more than national PBS expenditure.
| Medicine | Government benefit |
|---|---|
| teduglutide | $13.1M |
| amino acid synthetic formula supplemented with long chain polyunsaturated fatty acids and medium chain triglycerides | $9.1M |
Appraised elsewhere
NICE, in England and Wales, has appraised 1 technology for this condition, recommending 1 . A different committee, a different population and a different price: this is what has been looked at there, not a verdict on what happened here.
| Technology | Appraisal | Outcome | Date |
|---|---|---|---|
| teduglutideTeduglutide for treating short bowel syndrome | TA804 | recommended restricted | 2022-06 |
Conditions are classified by a language model from the indication text of each submission, so an individual label here can be wrong. Consumer input is read from the document's own consumer comments section: 3 of 4 decisions since 2014 carried some. Silence means no comment reached the committee through that facility, not that nobody was affected. More on how this was built.